RADIO MONROVIA BACK IN FULL SWING, After Relocation

first_imgThe Radio Monrovia 92.1 FM, which was off the airwaves for about four months due to its relocation, has finally reappeared in full swing with various educational, informative and entertaining programs aimed at maintaining peace and freedom of speech in the country.The owner of the radio station, Mr. Charles A. Snetter, made the disclosure yesterday, during an exclusive interview with the Daily Observer in Monrovia.Mr. Snetter said their relocation from Newport Street in Monrovia to Oldroad, Sinkor near the Haywood Mission School was to find a new site for better coverage.He established the station in 1993, during the Interim Government of National Unity (IGNU) of Dr. Amos C. Sawyer, when the nation was in a civil crisis. According to him, the station at the time played its part by informing both the people of Liberia and international community about happenings in Liberia.                                                         He further mentioned that the   new site has given them a far better broadcast coverage   with a new construction of a 70-foot Broadcast Tower and a 6000 Kilowatt Transmitter.Mr. Snetter assured his station’s listeners that as soon as they add the central electrical system, the station will broadcast for 24 hours daily.Currently they are only broadcasting for 19 hours. He then commended their listeners and supporters for their gestures, which enable them (Radio Monrovia Family) to get back on air.Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)last_img read more

Amgen Drug Gets Boost In Fiscal Cliff Legislation

first_imgAmgen Drug Gets Boost In Fiscal Cliff Legislation The New York Times: Medicare Pricing Delay Is Political Win For Drug MakerJust two weeks after pleading guilty in a major federal fraud case, Amgen, the world’s largest biotechnology firm, scored a largely unnoticed coup on Capitol Hill: Lawmakers inserted a paragraph into the “fiscal cliff” bill that did not mention the company by name but strongly favored one of its drugs. The language buried in Section 632 of the law delays a set of Medicare price restraints on a class of drugs that includes Sensipar, a lucrative Amgen pill used by kidney dialysis patients (Lipton and Sack, 1/19). This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.last_img read more